

Endologix Investor Relations Department 2 Musick Irvine, CA 92618 United States

Visit IR website ☐ Sign-up for Email alerts ☐

5.10
4:00 PM ET Oct 20, 2017
0.08 🕈 (+1.594%)
5.03 - 5.17
4.08 - 12.74
372,699

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

Addressing a signi... (more)

Stock Performance



Press Releases [View all]

Oct 19, 2017

Endologix Appoints John Onopchenko as Chief Operating Officer

Oct 10, 2017

Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017

Oct 6, 2017

Endologix Receives IDE Approval for the
EVAS2 Confirmatory Clinical Study to
Evaluate the Nellix® EndoVascular
Aneurysm Sealing System

Sep 21, 2017

Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use

Sep 11, 2017

Endologix Announces Collaboration

Agreements with Japan Lifeline for the

Development and Commercialization of

Thoracic Endovascular Systems in Japan

Upcoming Events [View all]

Nov 7, 2017 4:30 PM ET

Endologix 2017 Third Quarter Financial Results

Conference Call

Financials [View all]

Second Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

May 1, 2017

Proxy Statement (DEF 14A)

Aug 4, 2017

Quarterly Report (10-Q)

May 5, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)